

### **AMENDMENTS TO THE CLAIMS**

Please replace the claims, including all prior versions, with the listing of claims below.

#### **LISTING OF CLAIMS:**

- 1-21 (Cancelled)
22. (Previously Presented) A method of treating, managing or preventing obstructive lung disease comprising:  
administering to a patient a pharmaceutical composition comprising an effective amount of (a) Mycobacterium w or (b) a constituent of Mycobacterium w .
23. (Previously Presented) The method of claim 22, wherein the method is for treating, managing or preventing asthma.
24. (Previously Presented) The method of 23, wherein the method is for delaying attacks of asthma.
25. (Previously Presented) The method of 23, wherein the method is for reducing the requirement of drugs used to improve lung function during the management of asthma.
26. (Previously Presented) The method of claim 23, wherein the method is for improving lung function in the presence or absence of other drugs.
27. (Previously Presented) The method of claim 23, wherein the asthma is bronchial asthma.
28. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition comprises an admixture of Mycobacterium w and constituents of mycobacterium w prepared by cell disruption.
29. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition comprises constituents of Mycobacterium w prepared by cell disruption.
30. (Previously Presented) The method of claim 28, wherein the constituents of Mycobacterium w are prepared by sonication or high pressure fractionometer.

39. (Previously Presented) The method of claim 38, wherein the surfactant is polyoxvethylene sorbitan monooleate (Tween 80) or Triton X100.

40. (Previously Presented) The method of claim 38, wherein the surfactant is present in the pharmaceutical composition in a concentration of up to 0.4%.

41. (Previously Presented) The method of claim 38, wherein the surfactant is present in the pharmaceutical composition in a concentration of up to 0.1%.

42. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition further comprises a preservative.

43. (Previously Presented) The method of claim 42, wherein the preservative is Thiomerosal and is present in a concentration of 0.01% w/v.

44. (Previously Presented) The method of claim 22, wherein the Mycobacterium w is dead mycobacterium w.

45. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising at least  $10^5$  Mycobacterium w.

46. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising at least  $10^7$  Mycobacterium w.

47. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising between  $10^8$  and  $10^9$  Mycobacterium w.

48. (Original) The method of claim 22, wherein the constituent of Mycobacterium w is prepared by cell disruption, solvent extraction, or enzymatic extraction.